Meeting
2022 ASCO Annual Meeting
Indirect comparisons of triplet therapy as compared to novel hormonal therapy doublets in patients with metastatic castration sensitive prostate cancer.
Authors
Syed Arsalan Ahmed Naqvi
Mayo Clinic, Phoenix, AZ
Syed Arsalan Ahmed Naqvi , Zaryab Bin Riaz , Anum Riaz , Mahnoor Islam , Rabbia Siddiqi , Waleed Ikram , Muhammad Daim Bin Zafar , Parminder Singh , Irbaz Bin Riaz , Alan Haruo Bryce
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5083)
DOI
10.1200/JCO.2022.40.16_suppl.5083
Abstract #
5083
Poster Bd #
266
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
First Author: Syed Arsalan Ahmed Naqvi
Poster
2022 ASCO Annual Meeting
Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.
First Author: Deniz Can Guven
Poster
2022 ASCO Genitourinary Cancers Symposium
Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing intensified androgen deprivation therapy (ADT).
First Author: Umang Swami
Poster
2022 ASCO Genitourinary Cancers Symposium
Triplet therapy in metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
First Author: Syed Arsalan Ahmed Naqvi